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Abstract Prostate cancers harboring DNA repair gene alterations are particularly sensitive
to PARP inhibitor treatment. We report a case of an advanced prostate cancer patient
profiled within the NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication
Research) precision oncology program using next-generation sequencing. Comprehensive
genomic and transcriptomic analysis identified a pathogenic germline PALB2 variant as well
as a mutational signature associated with disturbed homologous recombination together
with structural genomic rearrangements. A molecular tumor board identified a potential
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benefit of targeted therapy and recommended PARP inhibition and platinum-based che-
motherapy. Single-agent treatment with the PARP inhibitor olaparib as well as subsequent
combination with platinum-based chemotherapy resulted in disease stabilization and sub-
stantial improvement of clinical symptoms. Upon progression, we performed whole-exome
and RNA sequencing of a liver metastasis, which demonstrated up-regulation of several
genes characteristic for the neuroendocrine prostate cancer phenotype as well as a novel
translocation resulting in an in-frame, loss-of-function fusion of RB1. We suggest that mul-
tidimensional genomic characterization of prostate cancer patients undergoing PARP inhib-
itor therapy will be necessary to capture and understand predictive biomarkers of PARP
inhibitor sensitivity and resistance.
[Supplemental material is available for this article.]
INTRODUCTION
Withgrowingevidence for the clinical activityof PARP inhibitors in several cancer entities,mu-
tations in genes involved in HR are increasingly recognized as possible biomarkers, although
the molecular events responsible for the development of resistance are incompletely
understood (Lord and Ashworth 2017). Advanced prostate cancer is often characterized by
germline and somatic alterations of genes involved in DNA repair via homologous re-
combination (HR) (Pritchard et al. 2016), which have also been associated with sensitivity to
poly(ADP-ribose) polymerase (PARP) inhibition in advanced disease. These data also suggest
that a substantial proportion of advanced prostate cancer patients may display “BRCAness”
and can benefit from PARP inhibition and/or platinum-based chemotherapy (Lord and
Ashworth 2016). Data from a phase 2 study of olaparib inmetastatic castration-resistant pros-
tate cancer (CRPC) revealed that 88% of patients that had a response to olaparib harbored
one or more deleterious alterations in DNA repair genes (Mateo et al. 2015). Here we report
the first case of a pathogenic germline PALB2 (partner and localizer of BRCA2) variant that
confers sensitivity to PARP inhibition in a patient with prostate cancer.
Clinical Presentation
The patient was diagnosed with locally advanced prostate adenocarcinoma at the age of 43.
His family history was not suggestive of a hereditary cancer predisposition syndrome. The
prostate-specific antigen (PSA) level at diagnosis was 76 ng/mL. Because of massive bladder
neck infiltration, the patient underwent initial transurethral resection, followed by 6 mo of
neoadjuvant combined hormonal therapy with leuprorelin and bicalutamide (PSA nadir
0.6 ng/mL) and radical retropubic prostatectomy. Even though the patient had a PSA re-
sponse, postoperative staging and grading exposed a large tumor with nodal metastasis
and positive surgical margins (pT4, pN1, cM0, R1) and a Gleason score of 5+4=9. Within a
month after radical surgery, and despite ongoing hormonal therapy, the patient became cas-
tration-refractory and was treated with six cycles of docetaxel chemotherapy. Unfortunately,
prostate-specific membrane antigen positron emission tomography after completion of che-
motherapy demonstrated disseminated bone and lymph nodemetastases. Because of a PSA
response during chemotherapy, four additional cycles of docetaxel were administered.
Zoledronic acid was added to the treatment regimen. The patient developed fatigue and
hisgeneral conditionworsenedbecauseofprogressivedisease andaccumulatingsideeffects
of chemotherapy (fatigue and muscular weakness leading to Eastern Cooperative Oncology
Group [ECOG] and World Health Organization [WHO] Score 3). Following PSA and radio-
graphic progression with hepatic metastases, therapy with abiraterone acetate and prednis-
olone was initiated, which could not bring about any treatment benefit.
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The primary tumor from the radical prostatectomy was analyzed using whole-genome
sequencing and made available for clinical interpretation within the NCT-MASTER
(Molecularly Aided Stratification for Tumor Eradication Research) program (Horak et al.
2017). We identified a pathogenic, heterozygous germline PALB2 mutation (Table 1) with
somatic loss of heterozygosity in the tumor as well as amutational signature suggestive of de-
fective DNA repair via homologous recombination when analyzing the entirety of somatic
SNVs (Alexandrov et al. 2013). This prompted a molecularly informed tumor board recom-
mendation by the NCT MASTER molecular tumor board of PARP inhibitor treatment with or
without platinum-based chemotherapyaswell as genetic counseling. Single-agent treatment
with thePARP inhibitorolaparib resulted in substantial improvementof clinical symptoms, and
onlymoderate sideeffects (e.g., anemiaCTCAEGrade2)wereobserved.Remarkably, thepa-
tient restarted physical activities and his general condition improved (ECOG/WHO Score 1).
However, staging after 6 wk revealed disease progression with 24.1% increase of target le-
sions. In addition, the PSA value increased during treatment with olaparib monotherapy
from 15.2 µg/L to 110 µg/L, whereas LDH decreased from 471 U/L to 297 U/L. Because of
the considerable clinical improvement, olaparib treatment was continued and cisplatin (30
mg/m2 i.v. weekly) was added. Magnetic resonance imaging after 2 mo of olaparib/cisplatin
therapy showed disease stabilization by Prostate Cancer Clinical Trials Working Group 3
(PCWG3) criteria (Fig. 1). Addition of cisplatin resulted in a mild decrease of PSA to 96.4 µg/L
aswell asof LDHto278U/L.However,worseninganemia (CTCAEGrade3) required transfusion
of red blood cells and we observed decreasing neutrophil counts (CTCAE Grade 2).
Three months thereafter, the lymphatic and hepatic metastases progressed and clinical
symptoms worsened. At time of radiological progression PSA had further decreased to
50.9 µg/L, whereas LDH dramatically increased to 1501 U/L. Given the patient’s young age
Table 1. Variant table
Gene Chromosome HGVS cDNA
HGVS
protein Variant type
Predicted
effect dbSNP Genotype ClinVar
PALB2 16 NM_024675.3:
c.509_510delGA
p.Arg170Ilefs Frameshift
deletion
Loss of
function
rs515726123 Germline
heterozygous
132267
Figure 1. Magnetic resonance imaging of liver metastases (A) before and (B) after 2 mo of olaparib/cisplatin
treatment. Two hepatic lesions were selected and their largest diameters measured in comparison according
to RECIST 1.1 criteria as defined by PCGW3. Sum of longest diameters of the two target lesions was 6.22 cm
before and 5.40 cm after olaparib/cisplatin treatment (13% decrease).
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and his desire to continue treatment, several experimental salvage regimens were adminis-
tered. However, no durable stabilization of disease could be achieved and the patient died
5 mo later.
Germline and Somatic Genomic Alterations
To identify molecular alterations that could inform experimental therapy in this patient, we
used whole-genome and transcriptome sequencing data from the prostatectomy specimen
that were obtained at diagnosis within the ICGC early-onset prostate cancer project
(Weischenfeldt et al. 2013) as well as whole-exome and transcriptome sequencing data
from a liver metastasis that was obtained upon progression on PARP Inhibitor therapy two
and a half years later. Single nucleotide variants (SNVs), small insertions and deletions
(indels), copy-number variations (CNVs), genomic structural variations, and gene fusions
were interpreted with regard to their clinical significance and ranked according to therapeu-
tic relevance.
Analysis of the primary tumor revealed 14 somatic nonsynonymous SNVs and two
somatic indels including a known TP53 missense variant, NM_000546.5:c.451C>T,
p.(Pro151Ser) (rs28934874) in the DNA-binding domain, which has been previously de-
scribed as a pathogenic mutation in prostate cancer (Supplemental Table S1; Shi et al. 2002).
We detected a germline frameshift deletion in PALB2, NM_024675.3:c.509_510del,
p.Arg170Ilefs∗14 (rs515726123) (Table 1), which has already been described as a pathogenic
Polish founder mutation associated with a predisposition for breast and ovarian cancer
(Dansonka-Mieszkowska et al. 2010). This variant demonstrated somatic loss of heterozygos-
ity with a mutational frequency of 70% in the primary tumor tissue. PALB2 is responsible for
BRCA2 nuclear localization and DNA damage response (Xia et al. 2006) and serves as a mo-
lecular adaptor between BRCA1 and BRCA2 (Sy et al. 2009). Therefore, absence of PALB2
leads to impaired recruitment of BRCA2 and RAD51 to sites of DNA damage, making it
a bona fide tumor suppressor. Germline loss-of-function mutations of PALB2 have been pri-
marily associated with hereditary susceptibility to breast, ovarian, and pancreatic cancer
(Jones et al. 2009; Antoniou et al. 2014; Southey et al. 2016), whereas homozygous loss
of function leads to Fanconi anemia (Reid et al. 2007; Xia et al. 2007).
Interestingly, we detected no other genetic hallmarks of prostate cancer, such as a
TMPRSS2-ETS fusion or PTEN inactivation. We also observed prominent amplification (total
copy number of 6) of theMYC proto-oncogene on Chromosome 8q24 (Fig. 2A), a common
alteration in prostate cancer associated with increased aggressiveness (Van Den Berg et al.
1995; Jenkins et al. 1997; Fromont et al. 2013), which was accompanied by increasedMYC
mRNA expression. Another amplicon on Chromosome 2p24 encompassed the MYC family
memberMYCN. However,MYCNmRNA expression was not elevated in the primary tumor,
in agreement with the observation that MYC and MYCN activation are mutually exclusive
events in advanced prostate cancer (Boutros et al. 2015) and MYCN expression is often as-
sociated with a neuroendocrine phenotype (Beltran et al. 2016). Of note,MYCN expression
was increased 4.8-fold in the therapy-resistant metastasis as compared to the primary tumor.
Comparison of the primary and metastatic samples demonstrated no apparent evolution of
CNVs contributing to additional oncogenic events, whereas extensive genomic rearrange-
ments were evident at both time points (Fig. 2A). We also performed a supervised analysis
of known mutational signatures (Alexandrov et al. 2013) and observed a strong contribution
of signature Alexandrov-COSMIC 3, which is associated with defective HRDNA repair, to the
mutational catalog in both the primary tumor and the metastasis (Fig. 2B).
The liver metastasis harbored 69 somatic nonsynonymous SNVs and two somatic indels
(Supplemental Table S1). The TP53mutation as well as five other SNVs and both indels iden-
tified in the primary tumor could not be detected in the metastasis, suggesting subclonal
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selection and evolution of the primary tumor during therapy. However, the distribution of al-
lele frequencies of synonymous and nonsynonymous SNVs in both samples was influenced
mainly by the tumor cell content and similar between the two samples (Fig. 2C). Interestingly,
the metastasis carried a novel translocation, resulting in an in-frame fusion of RB1 exon 3 and
exon 2 of COL28A1, encoding a collagen subtype, and was predicted to cause loss of reti-
noblastoma protein function (Fig. 3). We also observed discrete changes in the transcription-
al profile, in particular up-regulation of several genes characteristic for the neuroendocrine
prostate cancer phenotype such asMYCN, AURKA, EZH2, and DNMT1 (Beltran et al. 2016).
CB
A
Figure 2. (A) DNA copy-number profiles of the primary tumor (upper panel) and metastasis (lower panel).
(B) Relative contributions of mutational signatures (Alexandrov-COSMIC, AC) in the primary tumor (upper pan-
el) and metastasis (lower panel) depicting the prevalence of the AC3 signature. (C ) Distribution of measured
allele frequencies of all somatic synonymous and nonsynonymous SNVs in both samples.
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DISCUSSION
Our observations suggest that deleterious germline PALB2 variants represent an actionable
target in metastatic CRPC and support extended genomic testing in this patient popula-
tion. CRPC has been reported to be a very heterogeneous entity and several molecular
subtypes have recently been defined (Aggarwal et al. 2017). Among these, tumors with
DNA repair alterations might be particularly amenable to precision oncology approaches
as a plethora of DNA repair genes may be linked to PARP inhibitor sensitivity. Recent stud-
ies have established the occurrence of germline PALB2mutations in prostate cancer as well
as the sensitivity of other PALB2 deficient tumor entities to PARP inhibition (Erkko et al.
2007; Mateo et al. 2015). However, not every patient with DNA repair defects may expe-
rience clinical benefit, and the identification and detailed characterization of predictive bio-
markers is an ongoing effort. A germline missense variant in the FANCA gene has been
associated with exceptional response to platinum in neuroendocrine prostate cancer
(Beltran et al. 2015). In our case, we observed an initial response to PARP inhibition com-
bined with platinum-based therapy, which was followed by progression of an aggressive
tumor resistant to further treatment and displaying newly acquired somatic genetic alter-
ations typically associated with neuroendocrine prostate cancer, such as an inactivating
RB1 fusion and elevated MYCN expression (Tan et al. 2014; Beltran et al. 2016). We did
not find evidence for restoration of HR proficiency leading to secondary resistance to ola-
parib. We also hypothesize that resistance to PARP inhibition in prostate adenocarcinoma
with “BRCAness” might co-occur with the emergence of neuroendocrine transdifferentia-
tion (Akamatsu et al. 2018).
Figure 3. Fusion between exon 3 of RB1 and exon 2 of COL28A1. Upper panels show the sequencing cov-
erage and exon structure of the RB1 and COL28A1 as well as the structure of the putative fusion transcript.
Chromatogram of the Sanger sequencing showing the nucleotide sequence of the fusion region is shown
below.
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In summary, this comprehensive genomic and transcriptomic analysis indicates that path-
ogenic germlinemutations in PALB2 are associated with hallmarks of defective HR, including
extensive structural genomic rearrangements and enrichment of specific mutational signa-
tures, and might predict response to PARP inhibition as well as platinum-based chemother-
apy.We propose thatmultidimensional genomic characterization of prostate cancer patients
undergoing PARP inhibitor therapy will be necessary to define the entire spectrum of predic-
tive biomarkers.
METHODS
Next-Generation Sequencing, Bioinformatic Analysis, and Target Validation
Whole-genome,whole-exome, andRNAsequencingwereperformedasdescribedprevious-
ly (Weischenfeldt et al. 2013; Kordes et al. 2016). The fusion transcript was validated by
Sanger sequencing. SNVs and indels were identified using previously reported bioinfor-
matics pipelines (Weischenfeldt et al. 2013). Structural variants were called with CREST
(Wang et al. 2011). CNVs were extracted from whole-exome sequencing data with CNVkit
(version 0.8.3.dev0). For the extraction of CNVs from whole-genome sequencing data we
used our in-house CNV calling pipeline ACEseq (version 1.0.189) (Kleinheinz et al. 2017). A
supervised analysis of mutational signatures to determine the contributions of known muta-
tional signatures to themutational catalog of individual samples was performed as described
previously (Dieter et al. 2017). RNA-sequencing reads were mapped to the GRCh37.p13 as-
sembly of the human reference genome using STAR 2.4.1c with the following alignment pa-
rameters:–outFilterMultimapNmax 10 –outFilterScoreMinOverLread 0.66 –outFilterMatch
Nmin 0 –outFilterMatchNminOverLread 0.66 –outFilterMismatchNmax 10 –outFilter
MismatchNoverLmax 0.3 –clip5pNbases 0 –clip3pNbases 0 –clip3pAfterAdapterNbases 0
–clip3pAdapterSeq AGATCGGAAGAG –clip3pAdapterMMp 0.1 –seedSearchLmax 0
–seedSearchStartLmax 50 –alignIntronMin 21 –alignIntronMax 0 –alignMatesGapMax 0
–alignEndsType Local –alignSoftClipAtReferenceEnds No –chimSegmentMin 15 –chim
ScoreMin 1 –chimJunctionOverhangMin 15. The expression of genes annotated in the
GencodeV19 gene model was quantified with featureCounts (version 1.4.6-p2) (Liao et al.
2014). High-confidence gene fusion predictions were extracted from chimeric alignments
produced by STAR using our in-house pipeline Arriba (version 0.8), which removes recurrent
alignment artifacts, transcript variants also observed in normal tissue, and reads with low se-
quence complexity as well as events with short anchors or breakpoints in close proximity or a
low number of supporting reads relative to the overall number of predicted events in a gene.
Sequencing coverage metrics are provided in Supplemental Table S2.
ADDITIONAL INFORMATION
Data Deposition and Access
The raw analytical data have been deposited in the European Genome-phenome Archive
(https://www.ebi.ac.uk/ega/datasets) under accession numbers EGAS00001000383 (prima-
ry tumor, patient ID EOPC-125) and EGAS00001003133 (metastasis). Oncological outcome
data were collected via the Progether PROM’s (patient reported outcome measurement) in-
terface (www.progether.com).
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